Pacira BioSciences, Inc. (PCRX) - Total Liabilities
Based on the latest financial reports, Pacira BioSciences, Inc. (PCRX) has total liabilities worth $554.64 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Pacira BioSciences, Inc. net asset momentum to track the company's year-over-year net asset growth rate.
Pacira BioSciences, Inc. - Total Liabilities Trend (2008–2025)
This chart illustrates how Pacira BioSciences, Inc.'s total liabilities have evolved over time, based on quarterly financial data. See Pacira BioSciences, Inc. free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
Pacira BioSciences, Inc. Competitors by Total Liabilities
The table below lists competitors of Pacira BioSciences, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Focus Lightings Tech Co Ltd
SHE:300708
|
China | CN¥2.22 Billion |
|
Equitas Small Finance Bank Limited
NSE:EQUITASBNK
|
India | Rs-60.73 Billion |
|
Ventyx Biosciences Inc
NASDAQ:VTYX
|
USA | $20.10 Million |
|
CSSC Offshore & Marine Engineering (Group) Co Ltd
F:GSZ
|
Germany | €33.91 Billion |
|
Altri SGPS SA
LS:ALTR
|
Portugal | €833.58 Million |
|
Far Eastern Department Stores Ltd
TW:2903
|
Taiwan | NT$96.16 Billion |
|
TravelSky Technology Limited
F:TVL
|
Germany | €8.57 Billion |
|
Zhejiang Garden Bio-chemical High-tech Co Ltd
SHE:300401
|
China | CN¥2.50 Billion |
Liability Composition Analysis (2008–2025)
This chart breaks down Pacira BioSciences, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Pacira BioSciences, Inc. (PCRX) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.73 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.85 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.46 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Pacira BioSciences, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Pacira BioSciences, Inc. (2008–2025)
The table below shows the annual total liabilities of Pacira BioSciences, Inc. from 2008 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $571.81 Million | -26.23% |
| 2024-12-31 | $775.17 Million | +10.07% |
| 2023-12-31 | $704.26 Million | -22.28% |
| 2022-12-31 | $906.19 Million | -32.62% |
| 2021-12-31 | $1.34 Billion | +105.39% |
| 2020-12-31 | $654.83 Million | +37.53% |
| 2019-12-31 | $476.12 Million | +29.34% |
| 2018-12-31 | $368.13 Million | +5.51% |
| 2017-12-31 | $348.89 Million | +102.27% |
| 2016-12-31 | $172.49 Million | +0.74% |
| 2015-12-31 | $171.23 Million | +10.52% |
| 2014-12-31 | $154.93 Million | +20.50% |
| 2013-12-31 | $128.57 Million | +178.30% |
| 2012-12-31 | $46.20 Million | -29.17% |
| 2011-12-31 | $65.22 Million | -43.26% |
| 2010-12-31 | $114.94 Million | +71.81% |
| 2009-12-31 | $66.90 Million | +55.40% |
| 2008-12-31 | $43.05 Million | -- |
About Pacira BioSciences, Inc.
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension ind… Read more